DBV Technologies S.A. (DBVT)

Market Cap	1.27B +1,393.4%
Revenue (ttm)	5.50M -56.0%
Net Income	-125.13M
EPS	-1.06
Shares Out	168.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	352,072
Open	21.22
Previous Close	21.46
Day's Range	20.25 - 21.61
52-Week Range	3.82 - 26.19
Beta	-0.19
Analysts	Buy
Price Target	31.75 (+49.34%)
Earnings Date	Oct 28, 2025

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT
• Website: https://www.dbv-technologies.com

Financial Performance

In 2024, DBV Technologies's revenue was $4.15 million, a decrease of -73.61% compared to the previous year's $15.73 million. Losses were -$113.92 million, 56.6% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price target is $31.75, which is an increase of 49.34% from the latest price.

Price Target

$31.75

(49.34% upside)

Analyst Consensus: Buy